Asset
PATIDEGIB
Sol-Gel Technologies Ltd. Ordinary Shares
Revenue
No revenue reported in loaded filings.
Clinical trials (4)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT04155190 | phase2 | terminated | 2019-12-20 | 2021-04-23 | Sol-Gel Technologies, Ltd. | A Study of Patidegib Topical Gel, 2%, for the Reduction of Disease Burden of Persistently Developing Basal Cell Carcinomas in Patients With Non-Gorlin High Frequency BCC |
| NCT06050122 | phase3 | active_not_recruiting | 2024-03-17 | 2026-10-01 | Sol-Gel Technologies, Ltd. | Efficacy and Safety of Patidegib Gel 2% for Preventing Basal Cell Carcinomas on the Face of Adults With Gorlin Syndrome |
| NCT04308395 | phase3 | terminated | 2020-06-03 | 2021-07-14 | Sol-Gel Technologies, Ltd. | Extension Study of Patidegib Topical Gel, 2% in Subjects With Gorlin Syndrome (Basal Cell Nevus Syndrome) |
| NCT03703310 | phase3 | completed | 2019-02-19 | 2020-12-28 | Sol-Gel Technologies, Ltd. | Study of Patidegib Topical Gel, 2%, for the Reduction of Disease Burden of Persistently Developing Basal Cell Carcinomas (BCCs) in Subjects With Basal Cell Nevus Syndrome (Gorlin Syndrome) |
FDA applications (0)
This company has no applications containing this asset.